Dawnrays Pharmaceutical (Holdings) Ltd. announced that Ms. Li Kei Ling, the chairman of the company, submitted her resignation as the chief executive officer of the company due to the need to devote more time and effort to focus on executing the overall developmental strategies of the company and its subsidiaries from April 18, 2016, but remains as the chairman of the Board and an executive Director of the company, the chairman of the Nomination Committee and a member of the Remuneration Committee of the company, the chairman of the board of the company's subsidiaries. The Board is also announced that Mr. Chen Shaojun, the executive vice president of the company, has been appointed as the chief executive officer of the company with effect from April 18, 2016. Chen Shaojun joined sales and marketing department of Suzhou Dawnrays Pharmaceutical Company Limited, a subsidiary of the Company, in August 2002 as area manager and was responsible for developing area market of the Group's new specific medicines and managing sales business.

Chen has long specialized in sales promotion, network building, brand upgrading, planning and managing of business development in China pharmaceutical market.